| Source: |
| Type: |
| Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms: 1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion. 2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue. 3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment. 4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream. 5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body. 6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection. 7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs. 8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis. |
| 8553- | Matr, | Research progress on the pharmacological effects of matrine |
| - | Review, | Nor, | NA |
| 8550- | Matr, | Matrine improves the hepatic microenvironment and reverses epithelial-mesenchymal transition in hepatocellular carcinoma by inhibiting the Wnt-1/β-catenin signaling pathway |
| - | vitro+vivo, | Liver, | HUH7 |
| 8547- | Matr, | Matrine in cancer therapy: antitumor mechanisms and nano-delivery strategies |
| - | Review, | Var, | NA |
| 8639- | MBZ, | Repurposing mebendazole to reprogram oncogenic and tumor-suppressor networks: Multi-cancer insights from ENOX2, MMP2, RASSF1A, WFDC10A and METTL7A |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | AML, | K562 |
| 8821- | MCP, | Rad, | Modified Citrus Pectin as a Potential Sensitizer for Radiotherapy in Prostate Cancer |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 8819- | MCP, | PacT, | Pectasol‐C Modified Citrus Pectin targets Galectin‐3‐induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids |
| - | in-vitro, | Ovarian, | SKOV3 |
| 8716- | MeJa, | Methyl jasmonate abolishes the migration, invasion and angiogenesis of gastric cancer cells through down-regulation of matrix metalloproteinase 14 |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | MKN-28 |
| 8761- | MeSA, | Methylseleninic Acid Suppresses Breast Cancer Growth via the JAK2/STAT3 Pathway |
| - | in-vitro, | BC, | 4T1 |
| 6538- | MeSal, | ASA, | Salicylate induces AMPK and inhibits c-MYC to activate a NRF2/ARE/miR-34a/b/c cascade resulting in suppression of colorectal cancer metastasis |
| - | in-vitro, | CRC, | NA |
| 2384- | MET, | Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication |
| - | in-vitro, | Thyroid, | BCPAP | - | in-vivo, | NA, | NA | - | in-vitro, | Thyroid, | TPC-1 |
| 2378- | MET, | Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway |
| - | in-vitro, | SCC, | CAL27 | - | in-vivo, | NA, | NA |
| 2375- | MET, | Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling |
| - | in-vitro, | GC, | SGC-7901 |
| 2387- | MET, | GEM, | Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis |
| - | in-vitro, | CCA, | HCC9810 |
| 970- | MET, | Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer |
| - | in-vitro, | BC, | NA |
| 5247- | MF, | Anticancer Activity by Magnetic Fields: Inhibition of Metastatic Spread and Growth in a Breast Cancer Model |
| - | in-vivo, | BC, | MDA-MB-468 |
| 3470- | MF, | Pulsed electromagnetic fields inhibit IL-37 to alleviate CD8+ T cell dysfunction and suppress cervical cancer progression |
| - | in-vitro, | Cerv, | HeLa |
| 3500- | MF, | Moderate Static Magnet Fields Suppress Ovarian Cancer Metastasis via ROS-Mediated Oxidative Stress |
| - | in-vitro, | Ovarian, | SKOV3 |
| 3478- | MF, | One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study |
| - | Trial, | BC, | NA | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | C2C12 |
| 4354- | MF, | doxoR, | Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach |
| - | in-vivo, | BC, | MDA-MB-231 | - | in-vivo, | BC, | MCF7 |
| 5242- | MFrot, | Rotating magnetic field downregulating type XI collagen to suppress triple-negative breast cancer metastasis by inactivating the ITGB1/FAK/YAP signaling pathway |
| - | in-vitro, | BC, | NA |
| 205- | MFrot, | MF, | Intermittent F-actin Perturbations by Magnetic Fields Inhibit Breast Cancer Metastasis |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 516- | MFrot, | immuno, | MF, | Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth |
| - | vitro+vivo, | GBM, | U87MG |
| 8461- | Mg, | Effects of Salivary Mg on Head and Neck Carcinoma via TRPM7 |
| - | vitro+vivo, | SCC, | CAL27 | - | in-vitro, | Laryn, | FaDu |
| 9087- | MGF, | Mangiferin in human disease: Multifaceted mechanisms and applications (Review) |
| - | Review, | Var, | NA |
| 8669- | MLT, | Melatonin in lung cancer: integrating molecular mechanisms, tumor microenvironment regulation, apoptotic signaling, and therapeutic opportunities |
| - | Review, | Lung, | NA |
| 8671- | MLT, | Targeting mitochondrial metabolism in renal cell carcinoma with melatonin: Preclinical evidence and clinical perspectives |
| - | Review, | RCC, | NA |
| 8670- | MLT, | Antitumor Effects of Melatonin in Luminal and Triple-Negative Breast Cancer Cells: Metabolic Reprogramming, Redox Regulation, and Cellular Dynamics |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 8690- | MLT, | Melatonin inhibits proliferation, migration, and invasion by inducing ROS-mediated apoptosis via suppression of the PI3K/Akt/mTOR signaling pathway in gallbladder cancer cells |
| - | vitro+vivo, | Gall, | NOZ |
| 8686- | MLT, | CAP, | Non-thermal plasma-treated melatonin inhibits the biological activity of HCC cells by increasing intracellular ROS levels and reducing RRM2 expression |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | HUH7 |
| 8673- | MLT, | Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications |
| - | Review, | GC, | NA |
| 8675- | MLT, | Melatonin combined with antineoplastic drugs or natural products for cancer treatment: An update |
| - | Review, | Var, | NA |
| - | in-vivo, | Bladder, | NA |
| 8906- | MOR, | Morin, a avonoid from Moraceae, suppresses growth and invasion of the highly metastatic breast cancer cell line MDA-MB-231 partly through suppression of the Akt pathway |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 8864- | MOR, | Morin, a flavonoid from Moraceae, suppresses growth and invasion of the highly metastatic breast cancer cell line MDA-MB‑231 partly through suppression of the Akt pathway |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 8885- | MOR, | Anti-Inflammatory and Anti-Migratory Effects of Morin on Non-Small-Cell Lung Cancer Metastasis via Inhibition of NLRP3/MAPK Signaling Pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 8880- | MOR, | Morin, a Natural Flavonoid, Activates the PINK1/Parkin Pathway to Induce Mitophagy, Promote Apoptosis, and Suppress Cancer Stemness in Pancreatic Cancer |
| - | in-vitro, | PC, | NA |
| 8773- | MSM, | Methylsulfonylmethane (organic sulfur) induces apoptosis and decreases invasiveness of prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 8937- | MushCha, | Effects of Inonotus obliquus Polysaccharides on Proliferation, Invasion, Migration, and Apoptosis of Osteosarcoma Cells |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | OS, | U2OS |
| 8944- | MushCha, | Inonotus obliquus-derived polysaccharide inhibits the migration and invasion of human non-small cell lung carcinoma cells via suppression of MMP-2 and MMP-9 |
| - | in-vitro, | Lung, | A549 |
| 8957- | mushLions, | Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review |
| - | Review, | Nor, | NA |
| 8961- | mushLions, | A Novel Erinacine S Derivative from Hericium erinaceus Overcomes Chemoresistance in Colorectal Cancer Cells by Enhancing TRAIL/TNFR1/DR5 Expression through Histone Acetylation |
| - | in-vivo, | CRC, | NA |
| - | in-vitro, | Lung, | EAhy926 |
| 8960- | mushLions, | Recent Advances in Erinacine A: Preparation, Biological Activities, and Biosynthetic Pathway |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 9307- | MushMait, | Antitumoral Effects of D-Fraction from Grifola Frondosa (Maitake) Mushroom in Breast Cancer |
| - | in-vitro, | BC, | NA |
| 5613- | NaHCO3, | The Potential Role of Systemic Buffers in Reducing Intratumoral Extracellular pH and Acid-Mediated Invasion |
| - | Study, | Var, | NA |
| 5599- | NaHCO3, | Acidity generated by the tumor microenvironment drives local invasion |
| - | in-vivo, | BC, | MDA-MB-231 | - | in-vitro, | CRC, | HCT116 |
| 5607- | NaHCO3, | Does Baking Soda Function as a Magic Bullet for Patients With Cancer? A Mini Review |
| - | Review, | Var, | NA |
| 6492- | Nimb, | Review on Molecular and Chemopreventive Potential of Nimbolide in Cancer |
| - | Review, | Var, | NA |
| 6489- | Nimb, | Nimbolide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model |
| - | in-vivo, | Pca, | DU145 | - | in-vivo, | Pca, | LNCaP |
| 4971- | Nimb, | Nimbolide, a Neem Limonoid, Is a Promising Candidate for the Anticancer Drug Arsenal |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:324 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid